Latham & Watkins Represents Amgen in US$24 Billion Senior Notes Offering to Fund Acquisition of Horizon Therapeutics
On February 15, 2023, Amgen Inc., one of the world’s leading biotechnology companies, priced an offering of US$24.0 billion aggregate principal amount of senior notes, consisting of eight tranches of senior notes. The proceeds of the notes will be used to fund Amgen’s acquisition of Horizon Therapeutics plc. The offering is the ninth largest corporate debt issuance and second largest healthcare corporate debt issuance in history, according to Dealogic.
Latham & Watkins LLP represented Amgen in the offering with a corporate team led by partners Charles Ruck and Greg Rodgers and counsel Charles Cassidy, with associates Matt DeSilva and Yulong Li.